Question 1

What is the Edmonton Obesity Staging System (EOSS) and how does it guide treatment?

Accepted Answer

The Edmonton Obesity Staging System (EOSS) is a 5-stage clinical tool that classifies obesity severity based on obesity-related comorbidities, functional impairment, and psychological burden — not BMI alone. It is the most clinically meaningful obesity assessment tool available to GPs and predicts mortality and treatment outcomes better than BMI. Stage 0 — No apparent risk factors: lifestyle counselling and prevention Stage 1 — Subclinical risk factors (borderline hypertension, pre-diabetes): lifestyle intervention, annual monitoring Stage 2 — Established chronic disease (T2DM, hypertension, OSA, NAFLD): active treatment, consider pharmacotherapy Stage 3 — Significant end-organ damage (CVD, diabetic nephropathy, severe OSA): intensive treatment, bariatric referral discussion Stage 4 — Severe/end-stage comorbidities (heart failure, end-stage renal disease): multidisciplinary specialist care Key insight: A patient with BMI 32 at EOSS Stage 3 has higher mortality risk than a patient with BMI 40 at EOSS Stage 0 — treatment urgency is driven by EOSS, not BMI alone.

Question 2

How much weight loss do GLP-1 agonists achieve, and which is most effective?

Accepted Answer

GLP-1 receptor agonists have transformed obesity pharmacotherapy, achieving weight loss outcomes that rival bariatric surgery in randomised controlled trials. They work by acting on hypothalamic appetite centres to reduce hunger, slow gastric emptying, and reduce the hedonic reward value of food. Semaglutide 2.4 mg (Wegovy) — STEP 1 trial: 14.9% mean weight loss at 68 weeks vs 2.4% placebo; 69% achieved ≥10% weight loss SELECT trial (2023): Semaglutide reduced major adverse cardiovascular events (MACE) by 20% in patients with established CVD and obesity — the first weight management drug to show CV mortality benefit Tirzepatide 15 mg (Mounjaro) — SURMOUNT-1 trial: 20.9% mean weight loss at 72 weeks vs 3.1% placebo — the largest weight loss ever demonstrated in a pharmacotherapy trial; 57% achieved ≥20% weight loss Liraglutide 3 mg (Saxenda): 5.4% weight loss at 56 weeks — older agent, largely superseded by semaglutide Critical point: Weight regain of 60–70% occurs within 1 year of stopping — frame as long-term treatment, not a short course NHS eligibility: BMI ≥35 (or ≥30 in high-risk ethnic groups) with at least one weight-related comorbidity

Question 3

What are the NICE NG246 criteria for bariatric surgery referral in primary care?

Accepted Answer

Bariatric surgery remains the most effective long-term treatment for severe obesity, achieving 60–80% excess weight loss at 2 years and T2DM remission in 50–80% of patients. Despite this, fewer than 1% of eligible patients in the UK are referred — GPs must close this gap. Standard threshold: BMI ≥40 kg/m², or BMI ≥35 kg/m² with a significant comorbidity (T2DM, hypertension, OSA, CVD, or joint disease) Expedited referral: T2DM diagnosed within the last 10 years — refer regardless of prior non-surgical treatment Ethnicity adjustment: Use BMI ≥32.5 kg/m² as the threshold for South Asian, Chinese, and Black African patients Psychological readiness required: Binge eating disorder (BED) must be identified and treated before surgery — screen with "Do you ever eat a large amount of food in a short time and feel out of control?" Post-op GP responsibilities: Annual nutritional bloods (B12, iron, calcium, vitamin D, zinc, copper), lifelong supplementation, medication review, mental health screening (suicide risk increases post-bariatric surgery) Procedure options: RYGB (gold standard, 70–80% EWL), Sleeve Gastrectomy (most common, 60–70% EWL), Tirzepatide/Semaglutide as bridge or alternative for those unfit for surgery

Question 4

Can Type 2 diabetes go into remission with lifestyle changes alone?

Accepted Answer

Yes — T2DM remission is achievable and should be an explicit treatment goal, not an afterthought. The Twin Cycle Hypothesis (Roy Taylor, Newcastle) explains the mechanism: excess caloric intake drives ectopic fat into the liver and pancreas, causing insulin resistance and beta-cell dysfunction. Both are reversible with sufficient weight loss. T2DM remission definition: HbA1c <48 mmol/mol sustained for ≥3 months without glucose-lowering medication DiRECT trial: Total diet replacement (825–853 kcal/day) for 12–20 weeks achieved remission in 46% at 1 year and 36% at 2 years Weight loss thresholds: 5% weight loss → modest HbA1c reduction; 10% → moderate remission likelihood (20–30%); 15% → high remission likelihood (40–50%); ≥20% → very high remission (>50%) NHS Low Calorie Diet Programme: Available for T2DM patients with BMI ≥27 (≥25 in South Asian patients) diagnosed within 6 years — GPs can refer directly Medication safety: Patients on sulphonylureas or insulin must have doses proactively reduced at diet initiation — hypoglycaemia risk is significant Semaglutide/tirzepatide as adjuncts: Work best combined with structured lifestyle support; not a substitute for it

Question 5

What dietary pattern is most effective for Type 2 diabetes and obesity management?

Accepted Answer

Total caloric deficit and weight loss are the dominant drivers of glycaemic improvement — the best diet is the one the patient can sustain long-term. Several evidence-based patterns are effective; the key is matching the approach to the patient's food culture, cooking skills, and personal preferences. Total Diet Replacement (TDR): Highest remission rates (DiRECT trial); 825–853 kcal/day via formula products for 12–20 weeks; requires structured support; not suitable in eating disorders Low-carbohydrate (<130 g/day): Reduces HbA1c by 5–6 mmol/mol more than control diets at 6 months; rapid postprandial glucose reduction even before weight loss; Diabetes UK formally endorses this approach Mediterranean pattern: 30% relative risk reduction in MACE (PREDIMED trial); best long-term cardiovascular evidence; dual benefit for T2DM with CVD comorbidity Plate Method (Diabetes UK): Half plate non-starchy vegetables, quarter lean protein, quarter slow-release carbohydrates; accessible first-consultation tool; no calorie counting required Medication safety with low-carb: Reduce sulphonylurea by 50% at initiation; monitor glucose daily; insulin doses may need rapid downward adjustment — involve diabetes team early Behaviour change principle: Implementation intentions ("If it is Tuesday at 6pm, then I will walk to the park") increase behaviour follow-through 2–3× compared to general intentions alone

Lifestyle Medicine Articles

About Lifestyle Medicine Articles

The Six Pillars of Lifestyle Medicine in Primary Care

Top Article

Obesity & Weight Management in Primary Care: A Complete Clinical Framework

More Lifestyle Medicine Articles

The DiRECT Trial & NHS Low Calorie Diet Programme: A GP Implementation Guide

Clinical FAQs